naa a22 4500 510779980 CHVBK 20180411083243.0 cr unu---uuuuu 180411e20131001xx s 000 0 eng 10.1007/s11892-013-0413-9 doi (NATIONALLICENCE)springer-10.1007/s11892-013-0413-9 Transplantation of Xenogeneic Islets: Are We There Yet? [Elektronische Daten] [Philip O'Connell, Peter Cowan, Wayne Hawthorne, Shounan Yi, Andrew Lew] Beta cell replacement therapy has been proposed as a novel therapy for the treatment of type 1 diabetes. The proof of concept has been demonstrated with successful islet allotransplantation. Islet xenotransplantation has been proposed as an alternative, more reliable, and infinite source of beta cells. The advantages of islet xenotransplantation are the ability to transplant a well differentiated cell that is responsive to glucose and the potential for genetic modification which focuses the treatment on the donor rather than the recipient. The major hurdle remains overcoming the severe cellular rejection that affects xenografts. This review will focus on the major advances that have occurred with genetic modification and the successful therapeutic strategies that have been demonstrated in nonhuman primates. Novel approaches to overcome cell-mediated rejection including biological agents that target selectively costimulation molecules, the development of local immunosuppression through genetic manipulation, and encapsulation will be discussed. Overall, there has been considerable progress in all these areas, which eventually should lead to clinical trials. Springer Science+Business Media New York, 2013 Transplantation nationallicence Xenogeneic islets nationallicence Type 1 diabetes nationallicence Islet xenotransplantation nationallicence O'Connell Philip Centre for Transplant and Renal Research, Westmead Millennium Institute, University of Sydney at Westmead Hospital, 2145, Westmead, NSW, Australia aut Cowan Peter Immunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia aut Hawthorne Wayne Centre for Transplant and Renal Research, Westmead Millennium Institute, University of Sydney at Westmead Hospital, 2145, Westmead, NSW, Australia aut Yi Shounan Centre for Transplant and Renal Research, Westmead Millennium Institute, University of Sydney at Westmead Hospital, 2145, Westmead, NSW, Australia aut Lew Andrew Walter and Eliza Hall Institute of Medical Research, 3052, Parkville, Victoria, Australia aut Current Diabetes Reports Springer US; http://www.springer-ny.com 13/5(2013-10-01), 687-694 1534-4827 13:5<687 2013 13 11892 https://doi.org/10.1007/s11892-013-0413-9 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11892-013-0413-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- O'Connell Philip Centre for Transplant and Renal Research, Westmead Millennium Institute, University of Sydney at Westmead Hospital, 2145, Westmead, NSW, Australia aut NATIONALLICENCE 700 1- Cowan Peter Immunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia aut NATIONALLICENCE 700 1- Hawthorne Wayne Centre for Transplant and Renal Research, Westmead Millennium Institute, University of Sydney at Westmead Hospital, 2145, Westmead, NSW, Australia aut NATIONALLICENCE 700 1- Yi Shounan Centre for Transplant and Renal Research, Westmead Millennium Institute, University of Sydney at Westmead Hospital, 2145, Westmead, NSW, Australia aut NATIONALLICENCE 700 1- Lew Andrew Walter and Eliza Hall Institute of Medical Research, 3052, Parkville, Victoria, Australia aut NATIONALLICENCE 773 0- Current Diabetes Reports Springer US; http://www.springer-ny.com 13/5(2013-10-01), 687-694 1534-4827 13:5<687 2013 13 11892 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer